Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

被引：0
|
作者：
Le, H. [1 ]
Coulter, J. [2 ]
Cappelleri, J. C. [2 ]
Lu, H. [3 ]
Quaife, M. [3 ]
Meginnis, K. [3 ]
Fernandez, G. [3 ]
Culver, K. [4 ]
Vaghela, S. [2 ]
Rifi, N. [2 ]
Stinchcombe, T. [5 ]
机构：
[1] Pfizer Inc, Fairfax, VA USA
[2] Pfizer Inc, New York, NY USA
[3] Evidera, Cambridge, England
[4] ALK Posit, Atlanta, GA USA
[5] Duke Hlth, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Preference; ALK; TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.05
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [1] PATIENT AND ONCOLOGIST PREFERENCES FOR ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (ALK plus ANSCLC) TYROSINE KINASE INHIBITORS (TKIS) TREATMENTS IN THE FIRST LINE (1L) SETTING
    Le, H.
    Coulter, J.
    Cappelleri, J.
    Lu, H.
    Quaife, M.
    Meginnis, K.
    Fernandez, G.
    Culver, K. W.
    Vaghela, S.
    Thomaidou, D.
    Stinchcombe, T.
    VALUE IN HEALTH, 2024, 27 (06) : S339 - S339
  • [2] UK and US Patient Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitors Treatments
    Culver, K. W.
    Montague, D.
    Le, H.
    Coulter, J.
    Cappelleri, J. C.
    Lu, H.
    Quaife, M.
    Meginnis, K.
    Fernandez, G.
    Vaghela, S.
    Rifi, N.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S706 - S707
  • [3] PATIENT PREFERENCES FOR NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENTS
    Bridges, J. F.
    Mohamed, A.
    Finnern, H. W.
    Woehl, A.
    Hauber, A. B.
    VALUE IN HEALTH, 2011, 14 (07) : A459 - A459
  • [4] Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer
    Bridges, John F. P.
    de la Cruz, Marie
    Pavilack, Melissa
    Flood, Emuella
    Janssen, Ellen M.
    Chehab, Nabil
    Fernandes, Ancilla W.
    FUTURE ONCOLOGY, 2019, 15 (34) : 3895 - 3907
  • [5] Salvage surgery following tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer
    Kobayashi, Masao
    Funaki, Soichiro
    Nagata, Hideki
    Furukawa, Mitsugi
    Morii, Eiichi
    Shintani, Yasushi
    SURGICAL CASE REPORTS, 2024, 10 (01):
  • [6] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [7] VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration.
    Yamamoto, K.
    Kuwahara, M.
    Yamamoto, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S666 - S667
  • [8] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [9] Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.
    Yabe, Michitoshi
    Kenmotsu, Hirotsugu
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Eriko
    Miyawaki, Taichi
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] ECONOMIC ANALYSIS OF THE USE OF CRIZOTINIB, A TYROSINE KINASE ALK INHIBITOR, IN THE TREATMENT OF ALK POSITIVE NON-SMALL CELL LUNG CANCER IN THE MEXICAN SETTING
    Gay-Molina, J. G.
    Sanchez-Kobashi, R.
    Mucino-Ortega, E.
    Gutierrez-Coln, C., I
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2012, 15 (07) : A422 - A422
12345